


超越  
共同





®

®

15

5

Organon Abbott

Palleon

2 FIC

ASTRUM-005 FDA

EMA

ADC enabling IND-

24,000L

GMP QP

2026

144,000L

22 32.1

91.1%


22

9.8

22




5.2













✓	57	48				
✓			/	/	/	.....



(1) AxC    AEC    -    AOC    -    ADC    SMC    Fusion Protein



代谢 糖尿病肾病, 肥胖, 痛风, NAFLD, 心衰等

网络生物学  
多重药理学


神经

阿尔茨海默病, 帕金森, 渐冻症等

肿瘤

肺癌, 乳腺癌, 肝癌, 结肠癌, 胰腺癌等





20



III



LS-SCLC III



MAA 23 EMA ES-SCLC



FDA



24 FDA BLA



III




4



10 18 KG Bio




23 14





FDA

HER2+



2022 5

150mg Top1000

85%

60mg 4 29

Top1000

35%

560 3,700

150mg/  
60mg/  
420mg/



Zercepac®

Tuzucip®

Trastucip®





i





JAMA  
Nature Medicine British Journal of  
Cancer



PD-1/PD-L1



27 110 30%  
~400

DTP




MSI-H

100mg/10ml/




2021

PD-1/PD-L1



PD-1/PD-L1

PD-1/  
PD-L1




®




2019.02

2022.03

(RA)



%\*



®  
®  
®

2022

/

22Q1 22Q2 22Q3 22Q4

\* IQVIA CHPA



100mg/10ml/  
500mg/50ml/



30

31

III

"  
"  
"

" ASSC

"

"


"



2022 2

Getz Pharma

11



40mg/0.8ml/



30

25



III

® PD-1





®



100mg/4ml/







3 ADC  
NC18

2 ADC

Biomarker  
® GC/EC CDx

Four horizontal lines for text input.

Three horizontal lines for text input.

Four horizontal lines for text input.

Three horizontal lines for text input.



	IND	I	II	III	NDA	
HLX61	HLX51 OX40	HLX10 <sup>(1)</sup> PD-1+LAG-3 +HLX26	HLX10 <sup>(1)</sup> PD-1+VEGF 1L +	HLX10 <sup>(1)</sup> PD-1 1L +	HLX10 <sup>(1)</sup> PD-1 1L +	PD-1 MSI-H <sup>(1)</sup>
HLX6018 GARP/TGF-	HLX13 CTLA-4	HLX10 <sup>(1)</sup> PD-1+GARP +HLX60 <sup>(2)</sup>	HLX10 <sup>(1)</sup> PD-1+EGFR +HLX07	HLX10 <sup>(1)</sup> PD-1 / +	HLX10 <sup>(1)</sup> PD-1 1L +	CD20 <sup>(12)</sup> <sup>(13)</sup>
HLX41 LIV1 ADC		HLX26 LAG-3	HLX07 <sup>(6)</sup> EGFR	HLX10 <sup>(1)</sup> + PD-1 1L	HLX02 HER2 <sup>(11)</sup>	HER2 <sup>(11)</sup> ✓
HLX42 EGFR ADC		HLX60 GARP	HLX22 + HER2+HER2	HLX10 <sup>(1)</sup> PD-1+VEGF 1L +		TNF- <sup>(14)</sup>
HLX43 PD-L1 ADC		HLX35 <sup>(3)</sup> EGFR x 4-1BB	HLX208 <sup>(7)</sup> BRAF V600E LCH/ECD	HLX04-O <sup>(8)</sup> VEGF		VEGF <sup>(15)</sup>
HLX44 Nectin4 ADC		HLX301 <sup>(4)</sup> PD-L1 x TIGIT	HLX208 <sup>(7)</sup> + HLX10 <sup>(1)</sup> BRAF V600E + PD-1	HLX11 HER2 <sup>(9)</sup>		
HLX80 STEAP1 ADC		HLX53 TIGIT		HLX14 RANKL <sup>(10)</sup>		
HLX309 Nectin4 x 4-1BB		HLX05 EGFR <sup>(5)</sup>				
HLX314 HER2xSialidase		HLX15 CD38				
HLX17 PD-1						

(1)

(8)  
Tuzucip® Trastucip®2022 3 NMPA  
Accord/ Cipla/ Jacobson/ mAbxience/ Eurofarma/ Abbott (12)

(9) KGbio/

(2)

(10) Organon  
/ FARMA DE COLOMBIA/ Eurofarma/ Abbott (13)

(3)

Binacea (4)

Organon (11)

(5)

(14)




(6) 30  
/Getz Pharma (15)


(7)


Zercepac®  
Eurofarma

OE +HQQLXV









LCH/ECD MAPK

50

LCH/ECD  
BRAF V600E



LCH ECD



HLX208 LCH ECD

CDE

6

pre-NDA


LCH/ECD

(BTD)



HLX208

NSCLC mCRC



LCH/ECD




Gaurav Goyal et al. *Blood*. 2020 May 28;135(22):1929-1945  
Carl E. Allen et al. *N Engl J Med*. 2018 August 30; 379(9): 856-868

---

HLX07

II

HLX07



OX40 (clustering)

PD1/PDL1




PD1/PDL1

2022 11 IND

HLX53 H

Tiragolumab Atezolizumab

PD-1 mCRC NSCLC



First-in-Class

IND

TGF

ADCC

GARP

Treg

First-in-Class

EGFR

T

NK

EGFR

HLX35

HLX301

Atezolizumab

2

Tiragolumab



ES-SCLC


nsNSCLC




nsNSCLC  
Pivotal

mCRC  
PoC

sqNSCLC - OS  
Pivotal







NK cell engager

PD-1/PD-L1

AXC  
(XXC)

ADC  
T cell engager



mRNA



Deep Data Driven Drug Discovery(5D)

Biocomputation Accelerated Molecule Design (BAMD)

ADC payload



1-10

0-1

1

2

3

4

5






EGFR

payload



PD1/PDL1

payload






规划总产能


50000吨/年




24,000L



24,000L



96,000L



松江基地



2022

( )

GMP



2019~



HLX04-O HLX11 HLX14




GMP





2023

PFS ADC  
CDMO


PAT









## RMB





2022	32.1	91.1%
		BD
	187.2%	
2022	23.7	104.4%



2022	26.8	79.0%
------	------	-------



®	2022	17.3	86.1%
®	2022	3	9
®	2022	5.5	2.1%
®	2022	0.5	134.5%
BD	2022	5.4	187.2%




OE

+HQOLXV



3,214.7	100.0%	1,682.5	100.0%	91.1%
2,675.4	83.2%	1,494.6	88.8%	79.0%
539.4	16.8%	187.8	11.2%	187.2%
(844.6)	(26.3%)	(522.7)	(31.1%)	61.6%
(1,049.3)	(32.6%)	(520.3)	(30.9%)	101.7%
(354.0)	(11.0%)	(280.6)	(16.7%)	26.2%
(1,394.5)	(43.4%)	(1,023.9)	(60.9%)	36.2%
(105.7)	(3.3%)	(84.8)	(5.0%)	24.6%
(693.9)	(21.6%)	(956.7)	(56.9%)	(27.5%)
(695.3)	(21.6%)	(984.1)	(58.5%)	(29.3%)









“ Henlius” “ ”

LOGO

Henlius, the representor or the provider does not make express or implied warranties, statements or representations on the content of this document (the content of this document may also include forward-looking statements), including





可负担的创新 值得信赖的品质

Reliable Quality  
Affordable Innovation

